Review



optum® de-identified electronic health record dataset (optum® ehr)  (Optum Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Optum Inc optum® de-identified electronic health record dataset (optum® ehr)
    Optum® De Identified Electronic Health Record Dataset (Optum® Ehr), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+electronic+health+record+dataset+optum+ehr/pm40664765-68-37-42?v=Optum+Inc
    Average 90 stars, based on 1 article reviews
    optum® de-identified electronic health record dataset (optum® ehr) - by Bioz Stars, 2026-08
    90/100 stars

    Images



    Similar Products

    optum® de-identified electronic health record dataset (optum® ehr)  (Optum Inc)
    90
    Optum Inc optum® de-identified electronic health record dataset (optum® ehr)
    Optum® De Identified Electronic Health Record Dataset (Optum® Ehr), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+electronic+health+record+dataset+optum+ehr/pm40664765-68-37-42?v=Optum+Inc
    Average 90 stars, based on 1 article reviews
    optum® de-identified electronic health record dataset (optum® ehr) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    de-identified electronic health record dataset optum® ehr  (Optum Inc)
    90
    Optum Inc de-identified electronic health record dataset optum® ehr
    De Identified Electronic Health Record Dataset Optum® Ehr, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+electronic+health+record+dataset+optum+ehr/pmc11836508__mmc1-40-2-6?v=Optum+Inc
    Average 90 stars, based on 1 article reviews
    de-identified electronic health record dataset optum® ehr - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    de-identified electronic health record dataset (optum ehr)  (Optum Inc)
    90
    Optum Inc de-identified electronic health record dataset (optum ehr)
    De Identified Electronic Health Record Dataset (Optum Ehr), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+electronic+health+record+dataset+optum+ehr/pmc11737733-194-75-79?v=Optum+Inc
    Average 90 stars, based on 1 article reviews
    de-identified electronic health record dataset (optum ehr) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    de-identified electronic health record dataset optum ehr  (Optum Inc)
    90
    Optum Inc de-identified electronic health record dataset optum ehr
    Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory <t>Electronic</t> Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
    De Identified Electronic Health Record Dataset Optum Ehr, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+electronic+health+record+dataset+optum+ehr/pmc11681708-92-7-11?v=Optum+Inc
    Average 90 stars, based on 1 article reviews
    de-identified electronic health record dataset optum ehr - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    optum® de-identified electronic health record (ehr) dataset  (Optum Inc)
    90
    Optum Inc optum® de-identified electronic health record (ehr) dataset
    Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory <t>Electronic</t> Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
    Optum® De Identified Electronic Health Record (Ehr) Dataset, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+electronic+health+record+dataset+optum+ehr/pm38583036-3-38-37?v=Optum+Inc
    Average 90 stars, based on 1 article reviews
    optum® de-identified electronic health record (ehr) dataset - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

    Journal: BMC Medical Research Methodology

    Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

    doi: 10.1186/s12874-024-02428-7

    Figure Lengend Snippet: Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

    Article Snippet: The EHR databases included Optum ® de-identified Electronic Health Record Dataset (Optum ® EHR) and IQVIA Ambulatory EMR (Amb EMR).

    Techniques:

    Attrition diagrams for inflammatory bowel diseases (IBD); patient attrition counts and proportions after sequential design choices applied Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; RA = rheumatoid arthritis; RA comparator = certolizumab pegol or tocilizumab; Remicade ® (m) = Remicade ® exposure with concurrent methotrexate; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

    Journal: BMC Medical Research Methodology

    Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

    doi: 10.1186/s12874-024-02428-7

    Figure Lengend Snippet: Attrition diagrams for inflammatory bowel diseases (IBD); patient attrition counts and proportions after sequential design choices applied Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; RA = rheumatoid arthritis; RA comparator = certolizumab pegol or tocilizumab; Remicade ® (m) = Remicade ® exposure with concurrent methotrexate; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

    Article Snippet: The EHR databases included Optum ® de-identified Electronic Health Record Dataset (Optum ® EHR) and IQVIA Ambulatory EMR (Amb EMR).

    Techniques:

    Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for RA primary analysis Key – Target: patients with inflammatory bowel diseases newly exposed to Remicade ® , Comparator: patients with inflammatory bowel diseases newly exposed to [golimumab, certolizumab pegol, ustekinumab, or vedolizumab], CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data

    Journal: BMC Medical Research Methodology

    Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

    doi: 10.1186/s12874-024-02428-7

    Figure Lengend Snippet: Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for RA primary analysis Key – Target: patients with inflammatory bowel diseases newly exposed to Remicade ® , Comparator: patients with inflammatory bowel diseases newly exposed to [golimumab, certolizumab pegol, ustekinumab, or vedolizumab], CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data

    Article Snippet: The EHR databases included Optum ® de-identified Electronic Health Record Dataset (Optum ® EHR) and IQVIA Ambulatory EMR (Amb EMR).

    Techniques:

    Risk of non-infectious uveitis (NIU) among patients with inflammatory bowel diseases (IBD) Key – PS: propensity score, OT: on-treatment, ITT: intention-to-treat, T: Remicade ® new users with IBD, C: golimumab, certolizumab pegol, ustekinumab, or vedolizumab new users with IBD, IR: incidence rate, PYs: person-years, CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR: Optum ® De-Identified Electronic Health Record, Pharmetrics: IQVIA Adjudicated Health Plan Claims Data

    Journal: BMC Medical Research Methodology

    Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

    doi: 10.1186/s12874-024-02428-7

    Figure Lengend Snippet: Risk of non-infectious uveitis (NIU) among patients with inflammatory bowel diseases (IBD) Key – PS: propensity score, OT: on-treatment, ITT: intention-to-treat, T: Remicade ® new users with IBD, C: golimumab, certolizumab pegol, ustekinumab, or vedolizumab new users with IBD, IR: incidence rate, PYs: person-years, CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR: Optum ® De-Identified Electronic Health Record, Pharmetrics: IQVIA Adjudicated Health Plan Claims Data

    Article Snippet: The EHR databases included Optum ® de-identified Electronic Health Record Dataset (Optum ® EHR) and IQVIA Ambulatory EMR (Amb EMR).

    Techniques: